# BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

Study · id `cardio:ct-nct06059638` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06059638](<https://clinicaltrials.gov/study/NCT06059638>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06059638

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 316 participants.

## Technical summary

Registry record NCT06059638. Randomized; triple masking; primary purpose treatment. Start 2023-12-27 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 316 participants (planned count; ClinicalTrials.gov record NCT06059638, source copy `cardio:ctgov-nct06059638-2026-10-02`, retrieved 2026-11-18)
- Started: 2023-12-27 (actual) (ClinicalTrials.gov record NCT06059638, source copy `cardio:ctgov-nct06059638-2026-10-02`, retrieved 2026-11-18)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06059638, source copy `cardio:ctgov-nct06059638-2026-10-02`, retrieved 2026-11-18)
- Completion: 2029-08 (anticipated) (ClinicalTrials.gov record NCT06059638, source copy `cardio:ctgov-nct06059638-2026-10-02`, retrieved 2026-11-18)
- Countries: United States; Australia; Belgium; China; Czechia; France; Germany; Hungary; Italy; Netherlands; New Zealand; Poland; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT06059638, source copy `cardio:ctgov-nct06059638-2026-10-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06059638-2026-10-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
- Acronym: BACKBEAT
- Condition: Hypertension
- Condition: Hypertension, Systolic
- Condition: Hypertension, Essential
- Intervention (Device): Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated
- Intervention (Device): Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Lead sponsor: Orchestra BioMed, Inc
- Lead sponsor class: INDUSTRY
- Collaborator: Medtronic
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: 51c9f128a918b70d1eca04e1579d3b742df675acfcb0c71cdd40d768e05b1354
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
